Latest Us Expansion News

Adveritas has secured a $2 million placement at a 42.9% premium to its last close, with the proceeds earmarked for product development, marketing and working capital. The funding comes as the company pushes beyond sports betting and gaming while managing delayed Brazilian customer payments.

ARB Corporation’s FY26 profit fell 5.2% as weaker Australian aftermarket and OEM sales outweighed modest export growth. The 4x4 accessories maker is relying on improved vehicle supply, US expansion and new product programs to rebuild momentum in FY27.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.

PainChek has expanded its Sabra relationship from two initial facilities to 23 US communities across five operators, covering 808 contracted memory care licences. The immediate test is whether those contracts become implemented recurring revenue by the end of 2026.

Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.

Ovanti has reported a A$23.61 million FY2026 loss, A$21.27 million in operating cash outflows and only A$291,867 in cash at year end. The ASX-listed fintech has abandoned BNPL globally, but says its continuing operations and proposed funding initiatives provide a basis to keep trading despite a material going-concern uncertainty.

IODM has secured the first 15 university commitments in its planned 283-university US rollout, while revenue rose 10.2% despite a sharp fall in UK international student visa applications. The onboarding is not yet revenue, but the December-quarter target gives investors a clear execution test.

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Metallium has completed a 12-hour campaign using three Flash Joule Heating reactors to process platinum-group-metal-bearing catalytic converter material under reactive chlorination conditions. The milestone advances the company’s scale-up program, but recovery results, product economics and feedstock grades remain unverified.

Peak Processing delivered its first positive Group EBITDA quarter in FY2026, but the turnaround remains financially fragile. The ASX-listed THC beverage manufacturer reported a $7.8 million statutory loss, negative operating cash flow and an explicit material uncertainty over its ability to continue as a going concern.

SQX Resources Limited (ASX:SQX) has emerged from a transformational year with two advanced US gold projects, broad shallow mineralisation at Red Bird and exceptional underground assays at Williams. The exploration gains came alongside a $1.83 million loss, falling cash and a further $2.47 million capital raising completed after year-end.